ADAG
Adagene Inc.
There isn't enough reported data to score ADAG yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
ADAG Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ADAG's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ADAG PE Valuation
ADAG has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
ADAG Forward outlook
There aren't enough analyst estimates for ADAG to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
ADAG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$0.30 | +$0.46 |
| Q2 2025 | -$0.51 | +$0.39 |
| Q4 2024 | -$0.76 | -$0.22 |
| Q2 2024 | -$0.90 | +$0.16 |
| Q1 2024 | -$0.72 | +$1.64 |
| Q4 2023 | -$0.54 | +$2.45 |
| Q3 2023 | -$0.80 | +$2.74 |
| Q2 2023 | -$1.06 | +$2.52 |
UNH has the stronger earnings trend. Trailing diluted EPS is down 142% for ADAG versus UNH down 8.5%.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
ADAG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2023 | $407.9K | -85% |
| Q3 2023 | $407.9K | -85% |
| Q2 2023 | $8.6M | +120% |
| Q1 2023 | $8.6M | +341% |
| Q4 2022 | $2.7M | -69% |
| Q3 2022 | $2.7M | -39% |
| Q2 2022 | $3.9M | +189% |
| Q1 2022 | $2M | +189% |
ADAG has the stronger quarterly revenue trend. Revenue is up 298% for ADAG versus down 0.4% for UNH.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1024% | N/A |
| Q4 2023 | -2289% | -1621 points |
| Q3 2023 | -2289% | -1621 points |
| Q2 2023 | -29% | +1196 points |
| Q1 2023 | -29% | +1196 points |
| Q4 2022 | -668% | -272 points |
| Q3 2022 | -668% | -272 points |
| Q2 2022 | -1225% | +1535 points |
ADAG's operating margin was −1024% last quarter, down 995 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over ADAG on profitability, with a higher operating margin.
ADAG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$14.9M | -$3.8M |
| Q4 2025 | -$4.5M | +$11.8M |
| Q2 2025 | -$11.1M | -$4.4M |
| Q4 2024 | -$16.3M | -$1.3M |
| Q2 2024 | -$6.7M | +$36K |
| Q1 2024 | -$6.7M | +$36K |
| Q4 2023 | -$15.1M | -196% |
| Q3 2023 | $0 | -100% |
UNH has the stronger cash trend. Its trailing FCF is up 5.2% versus its history, compared with ADAG at down 287%.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
ADAG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -23% | -13.7M shares |
| 1 year | +28% | +10M shares |
| 3 years | +30% | +10.4M shares |
| 5 years | +65% | +17.8M shares |
| Available history | +367% | +35.6M shares |
ADAG has 45M diluted shares, up 28% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over ADAG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
ADAG Net Leverage
ADAG's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ADAG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 9.4 | Oversold |
ADAG's weekly RSI is 36 (neutral) and its Stochastic is 9 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ADAG PE vs Healthcare Sector
ADAG has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
ADAG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.44 | 18% below |
| 20 week MA | $3.21 | 38% below |
| 50 week MA | $3.15 | 37% below |
| 100 week MA | $2.51 | 20% below |
| 200 week MA | $2.30 | 13% below |
ADAG is in a downtrend: it's below all five of its weekly moving averages, and 13% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over ADAG on trend strength, trading above more of its moving averages.
ADAG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $27.7 | $7.50 | -73% |
| 2022 | $7.50 | $1.26 | -83% |
| 2023 | $1.26 | $1.93 | +53% |
| 2024 | $1.93 | $1.96 | +1.6% |
| 2025 | $1.96 | $1.78 | -9.2% |
| 2026 YTD | $1.78 | $2.00 | +12% |
ADAG has finished lower in three of the last five years. It's up 12% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over ADAG on returns for 2026, with the stronger performance.